What the trial was testing
The FINCH 2 enrolled 449 patients with rheumatoid arthritis. The study was sponsored by Gilead Sciences and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
66% of patients taking filgotinib 200 mg had significant symptom improvement at 12 weeks.
JAMA · 2019 · NCT02873936
These findings — that had significant symptom improvement with filgotinib 200 mg versus 31% with placebo — were published in the JAMA and represent the headline result of the study.
Researchers tracked outcomes across 449 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with rheumatoid arthritis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Filgotinib is FDA-approved for rheumatoid arthritis under the brand name Jyseleca. It's an option for people whose symptoms haven't improved with other treatments. This trial showed it helped reduce joint pain and swelling in people who had already tried other medications. Talk to your rheumatologist about whether filgotinib might work for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open rheumatoid arthritis trials
Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders
The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression. Additionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.